CAR-T cell therapy has transformed treatment for some blood cancers, but solid tumors often resist it. A new study from Mayo Clinic researchers identifies a way to strip that resistance: restoring a specific thyroid hormone receptor in cancer cells. When this receptor is missing or inactive, tumors become better at concealing themselves from engineered immune cells.
The team found that re-expressing the receptor makes aggressive tumor cells more visible to CAR-T cells, allowing the therapy to recognize and attack them. The work suggests a potential combination strategy—pairing CAR-T infusion with drugs that reactivate the receptor—could improve outcomes for patients with hard-to-treat solid tumors.
The findings are preliminary and based on laboratory models, so clinical validation is still needed. But the approach offers a new angle on a long-standing obstacle: not just boosting the immune cells, but also unmasking the tumor. If confirmed in humans, it could broaden the reach of CAR-T therapy to a much wider range of cancers.